Study protocol for a pilot randomised controlled trial assessing prehospital whole blood versus component therapy in traumatic haemorrhage: SWiFT Canada (study of whole blood in frontline trauma) Authors: Yulia Lin, Michael Peddle, Jeannie Callum, Andrew Beckett, Luis Teodoro da Luz, Ian Drennan, Katerina Pavenski, Johnathan Mack, Melissa McGowan, Mahvareh Ahghari, Jason Smith, Laura Green, Charles D G Keown-Stoneman, Brodie Nolan, on behalf of the SWiFT Canada Investigators Published: 2025 ABSTRACT AbstractIntroductionMajor haemorrhage is the leading cause of preventable death in trauma, and prehospital blood transfusion may improve survival and outcomes for patients with prolonged out-of-hospital times. Globally, there is increasing interest in the use of whole blood in the prehospital environment, with randomised controlled trials ongoing. However, the results of these studies may not be generalisable to the longer out-of-hospital times seen in the Canadian trauma environment. The aim of this trial is to determine the feasibility of performing a randomised clinical trial evaluating the use of leukocyte-reduced whole blood transfusion compared with component blood transfusion in the Canadian prehospital environment. The secondary objective is to explore whether whole blood transfusion is better in reducing the proportion of patients who die or require massive transfusion within 24 hours.Methods and analysisThis is a multi-centre, open-label, randomised controlled feasibility trial. Patients aged 16 years or older will be eligible if they have suffered a major traumatic haemorrhage, are attended by the provincial air ambulance service and require a prehospital blood transfusion. The primary outcome is feasibility as measured by the following metrics: proportion of patients enrolled with full data collection, proportion of patients who received at least one prehospital transfusion prior to arriving at the receiving trauma centre, proportion of patients who completed transfusion of all assigned blood units, number of patients unable to be enrolled due to lack of whole blood availability and number of whole blood units produced for the study that were wasted or expired. The secondary outcome is a composite outcome of death (all-cause mortality) or receipt of massive transfusion (receipt of 10 units of blood or more) within the first 24 hours from randomisation. We plan to recruit 60 patients, with an anticipated post-randomisation exclusion of ~10 patients for traumatic cardiac arrest or who do not meet eligibility criteria.Ethics and disseminationProvincial ethics approval was obtained (Clinical Trials Ontario REB ID: CTO-4921). An opt-out consent model will be employed for participants. The SWiFT Canada trial will recruit 60 patients through the provincial air ambulance organisation in Ontario who are transported to one of the six participating lead trauma centres. It will investigate the feasibility of a pre-hospital transfusion clinical trial in Canada to compare the effectiveness of whole blood compared with component blood therapy in a future definitive trial.Trial registration numberClinicalTrials.gov: NCT06495294 (https://clinicaltrials.gov/study/NCT06495294), Clinical Trials Ontario: CTO-4921. STRENGTHS AND LIMITATIONS OF THIS STUDY This is the first randomised controlled trial in Canada to assess the feasibility of prehospital whole blood transfusion in trauma patients, using an established provincial air ambulance service. This is the first randomised controlled trial in Canada to assess the feasibility of prehospital whole blood transfusion in trauma patients, using an established provincial air ambulance service. The pragmatic design allows for real-world implementation of transfusion protocols in high-acuity, time-critical trauma care environments. The pragmatic design allows for real-world implementation of transfusion protocols in high-acuity, time-critical trauma care environments. The study incorporates robust data linkage between prehospital and in-hospital records to evaluate feasibility and process outcomes. The study incorporates robust data linkage between prehospital and in-hospital records to evaluate feasibility and process outcomes. The unblinded design may introduce potential bias in subsequent in-hospital care decisions and clinical documentation. The unblinded design may introduce potential bias in subsequent in-hospital care decisions and clinical documentation. The relatively small sample size and restriction to a single provincial air ambulance base may limit generalisability to other jurisdictions or ground-based EMS systems. The relatively small sample size and restriction to a single provincial air ambulance base may limit generalisability to other jurisdictions or ground-based EMS systems. Introduction Background Traumatic injuries affect people of all ages, genders, ethnicities and socioeconomic backgrounds. The Global Burden of Disease study showed that globally in 2019, there were more than 4.4 million deaths due to injury. Furthermore, unintentional injuries are the leading cause of death for people aged 5–29 years worldwide.1 2 Uncontrolled bleeding accounts for a significant proportion of these deaths, with approximately 20% occurring in the first 24 hours and 40% occurring within the first 30 days.3 Blood transfusion is a life-saving treatment in the management of bleeding patients before institution of definitive bleeding control. Blood transfusions typically involve the use of components—red blood cells (RBCs), plasma and platelets—all of which are obtained from donated whole blood (WB) and stored individually under different temperature conditions. Component separation ensures patients only receive what they need. On the other hand, WB contains all individual components in one bag, offering logistical advantages in both storage and administration, although the exact overall cellular content will not match that in individual components due to processing. The contribution of platelets in cold-stored WB has not been studied in clinical trials.4 Lastly, the use of components has a higher citrate load, with a lack of clarity whether this difference has a clinical impact.5 In the published randomised control trials (RCTs) to date, prehospital transfusion has shown mixed results in improving either laboratory or patient-important outcomes; however, there are suggestions that patients with prolonged transport >20 min may be more likely to benefit.610 In Ontario, patients who are bleeding at the scene of an incident may be transfused blood before they arrive at hospital by Ornge air ambulance paramedics via the blood-on-board programme. However, the optimal transfusion strategy (whether this should be RBC only, RBC+plasma, RBC+plasma+platelets or WB) in the prehospital setting has yet to be established. Transfusion practice across the country varies. A national Canadian study in 2023 found that of the six critical care transport organisations in Canada with a prehospital transfusion programme, all are carrying at least two units of group O Rh negative RBC, two services also carry thawed AB plasma and none carried WB or platelets prehospital.11 WB was transfused routinely during the First and Second World Wars within 24 hours of it being donated (known as fresh WB) before the development of component processing. By 1965, the development of separated blood components with a longer shelf-life than WB enabled targeted replacement therapy for deficiency of clotting proteins with plasma (for haemophilia) or RBC (for anaemia), and in so doing, it minimised the potential risks/side effects of receiving unnecessary blood components and made the logistics of supply and demand manageable for the blood manufacturing units. Canadian Blood Services (CBS) received Health Canada approval to manufacture WB in 2022 and initially restricted the product for military use. In May 2024, the National Advisory Committee on Blood and Blood Products recommended this restriction be lifted, with a prioritisation for WB use in clinical trials or studies to provide evidence for which patients are most likely to benefit from WB use, before expanding its use. Two systematic reviews, which compared the impact of WB transfusion versus blood component therapy on 24-hour and 30-day mortality for adult trauma patients with acute major haemorrhage, showed no clear benefit with WB transfusion.12 13 In these reviews, there was only one RCT with 107 patients, which was not powered to evaluate efficacy or safety. The combined data analysis from prehospital transfusion RCTs suggests that the survival benefit for prehospital transfusion is greatest in patients who received both RBC and plasma,14 in patients with blunt trauma15 and when prehospital times are longer than 20 minutes.6 The Canadian prehospital environment encapsulates this longer transport time (all air ambulance transports are over 20 min—average 30–45 min (unpublished data)), and thus severely injured patients in Canada may be more likely to benefit from prehospital blood transfusion. Outdating of unused blood products is a major concern. Expiry of 1 unit of WB is, in effect, the loss of multiple blood components (one RBC, one plasma and part of a platelet pool). If WB is reserved for one group of patients (in the prehospital environment), it is likely that the product outdating will be high unless it is also given to other patients who are bleeding in hospital (as is done for other blood components). The impact on the national blood inventory of diverting blood donations away from component production and toward WB production is unknown. The National Advisory Council on Blood and Blood Products recommends that component demand is always satisfied over WB production, due to lack of evidence for improved patient outcomes. Rationale for a feasibility trial As outlined briefly above, the evidence supporting prehospital transfusion practices is limited. To date, no pre-hospital transfusion clinical trial has been done in Canada. The evidence suggests that pre-hospital transfusion may improve patient outcomes in certain patient types when out-of-hospital times are longer than 20 min. This longer than 20 min transport time is highly representative of the air ambulance population across Canada, with average out of hospital times typically closer to 30–45 min. The Study of Whole blood in Frontline Trauma (SWiFT) trial is an RCT in the UK that recruited 900 patients across the UK and randomised to receive either 2 units of WB or 2 units of RBC and 2 units of plasma.16 It is anticipated that the out-of-hospital time from the SWiFT UK trial will be shorter than encountered in the Canadian prehospital environment, presenting a challenge with the generalisability of the study findings. Therefore, a feasibility study exploring the patient characteristics, transport times and mortality within the Canadian context is critical to inform the planning of a future larger prehospital transfusion randomised clinical trial. Objectives The primary objectives of the SWiFT Canada study are: To assess the proportion of patients enrolled in the study who received a prehospital transfusion and had full study data collected (feasibility target: >90% patients enrolled were able to link prehospital to in-hospital records and >90% complete data obtained). To assess the proportion of patients enrolled in the study who received a prehospital transfusion and had full study data collected (feasibility target: >90% patients enrolled were able to link prehospital to in-hospital records and >90% complete data obtained). To assess the number of patients who received transfusion of at least 1 unit of assigned blood products prior to arrival to receiving lead trauma hospital (LTH) (feasibility target: at least 1 unit of blood (WB, RBC or plasma) transfused prior to arrival >90% of the time). To assess the number of patients who received transfusion of at least 1 unit of assigned blood products prior to arrival to receiving lead trauma hospital (LTH) (feasibility target: at least 1 unit of blood (WB, RBC or plasma) transfused prior to arrival >90% of the time). To assess the number of patients who completed transfusion of all assigned blood products at the receiving LTH (feasibility target: >90% including those that had completed transfusion prior to arrival at hospital). To assess the number of patients who completed transfusion of all assigned blood products at the receiving LTH (feasibility target: >90% including those that had completed transfusion prior to arrival at hospital). To identify the number of patients screened for the study but not randomised due to lack of available group O negative WB. To identify the number of patients screened for the study but not randomised due to lack of available group O negative WB. To describe the distribution, redistribution and wastage of WB units produced for the study (feasibility target <10% wastage of WB units produced for the study). To describe the distribution, redistribution and wastage of WB units produced for the study (feasibility target <10% wastage of WB units produced for the study). The following secondary objectives of the study align with the SWiFT UK study: To determine the impact of prehospital administration of WB on the proportion of participants who experience death or massive transfusion at 24 hours, compared with the current standard of care (component blood therapy). To determine the impact of prehospital administration of WB on the proportion of participants who experience death or massive transfusion at 24 hours, compared with the current standard of care (component blood therapy). To determine the impact on mortality up to 90 days. To determine the impact on mortality up to 90 days. To determine the impact on morbidity up to 30 days. To determine the impact on morbidity up to 30 days. To determine the impact on hospital resource use up to discharge, including organ failure free days, time spent in critical care and total in-patient stay, blood components and additional haemostatic agents received. To determine the impact on hospital resource use up to discharge, including organ failure free days, time spent in critical care and total in-patient stay, blood components and additional haemostatic agents received. To assess the safety of prehospital transfusion by documenting all transfusion reactions/events within the first 14 days after randomisation and explore any different rates/types of transfusion reactions between patients who received WB versus component blood therapy. To assess the safety of prehospital transfusion by documenting all transfusion reactions/events within the first 14 days after randomisation and explore any different rates/types of transfusion reactions between patients who received WB versus component blood therapy. Methods and analysis Trial status The current trial protocol is V.1.0, dated 26 May 2024. The trial opened to recruitment on 16 December 2024. Recruitment is anticipated to run for 18 months, and therefore, the estimated completion date is 16 June 2026. Patient and public involvement We are currently in the process of performing community consultation regarding SWiFT Canada. This includes assessing the understanding of the Ontario trauma system, the role of the air ambulance service (AAS), the importance of blood transfusions, general thoughts on research and emergency waiver of consent. The results of these sub-studies will be reported at conferences, peer-reviewed publications and summarised in plain-language summaries at www.FIRST60.ca. Trial design SWiFT Canada is a multi-centre, interventional, randomised, unblinded, parallel controlled trial. In collaboration with the SWiFT UK team, the SWiFT Canada study will follow the SWiFT UK protocol but as adopted for the Canadian context. Trial setting The trial will be done in the province of Ontario, Canada. Ornge air ambulance service Responsible for treating patients on scene or modified scene and delivering the trial intervention prior to hospital admission. The AAS currently administers blood components as standard care for the treatment of suspected life-threatening bleeding. Recruitment will be done through the Toronto rotor-wing base (two AW-139 helicopters available 24 hours a day, each staffed by two critical care paramedics). Transfusion medicine laboratory site Responsible for supplying blood components in accordance with the randomisation procedure to Ornge AAS. This site is hospital-based at Sunnybrook Health Sciences Centre (SHSC), Transfusion Medicine and Tissue Bank, which supplies blood components to the participating Toronto rotor base of Ornge AAS. Receiving LTH sites Secondary care sites where participants will be admitted following trial treatment. These sites will be the designated LTHs (St Michael’s Hospital, SHSC, Hamilton General Hospital, London Health Sciences Centre, Kingston Health Sciences Centre and Health Science North Sudbury) that receive participants from the participating Ornge AAS Toronto rotor base. Unity Health Toronto data coordinating centre Responsible for overall study management, including study logistics, regulatory, contracts, finances, data coordination and management, patient withdrawal and study oversight for SWiFT Canada. All pre-hospital and in-hospital data will be sent to Unity Health Toronto (UHT) Data Coordinating Centre where study data will be reviewed, verified and entered into a REDCap database (housed within the Applied Health Research Centre (AHRC)), at UHT. Eligibility criteria The pragmatic nature of this trial means that the decision to administer the intervention will be based on clinician judgement and in accordance with the Ornge AAS usual criteria for initiation of blood transfusion. Participant inclusion criteria Patient who has suffered a traumatic injury. Patient who has suffered a traumatic injury. Attended by a participating Ornge AAS clinical team as scene or modified scene call. Attended by a participating Ornge AAS clinical team as scene or modified scene call. Requires pre-hospital blood transfusion to treat major traumatic haemorrhage. Requires pre-hospital blood transfusion to treat major traumatic haemorrhage. Participant exclusion criteria Paediatric (age <16 or transported to paediatric trauma centre (if age unknown)). Paediatric (age <16 or transported to paediatric trauma centre (if age unknown)). No intravenous or intraosseous access (should be assessed prior to opening box). No intravenous or intraosseous access (should be assessed prior to opening box). Knowledge that patient will object to being given blood transfusion for any reasons. Knowledge that patient will object to being given blood transfusion for any reasons. Blood already administered on-scene, prior to arrival of the participating Ornge AAS. Blood already administered on-scene, prior to arrival of the participating Ornge AAS. Interfacility transfer. Interfacility transfer. Intervention and comparator The trial will compare up to 2 units of WB (intervention arm) versus up to 2 units of RBC and 2 units of plasma (control arm). Following this, additional blood components should be administered as required at the discretion of the treating clinician. There is no ongoing direction for the type of transfusion therapy administered. Intervention arm (WB) The WB component will be manufactured by CBS, which is the main blood supplier of blood in Canada. In October 2022, Health Canada approved WB to be manufactured and distributed by CBS. WB, leukocytes reduced, is indicated for treatment of patients with clinically significant bleeding and has low anti-A and anti-B titres (less than a manual equivalent of 1:128). WB is not considered an investigational drug/product. The use of WB in the study is within Health Canada approved indications. The total volume of a WB unit is approximately 480 mL. The shelf life of WB is 21 days and the product should be stored at 1–6°C. WB will be collected from group O (Rh negative) male donors to mitigate against Transfusion-Related Acute Lung Injury (TRALI) risk. Once manufactured, the WB units will be transported to SHSC Transfusion Medicine Laboratory under continuous temperature control as per standard operating procedures and stored at 2–6°C for up to 21 days. Control arm (RBC and plasma) The control arm will consist of 2 units of RBC and 2 units of plasma. RBC and plasma are blood components that are supplied by CBS to SHSC Transfusion Medicine Laboratory that supports the Ornge AAS Toronto rotor base for this trial. Preparation and labelling of blood products Blood components (WB, RBC, plasma) will be prepared, labelled and issued by SHSC Transfusion Medicine Laboratory as per standard operating procedures. Administration of blood products WB may be administered via either the intravenous or intraosseous route, according to standard practice at Ornge AAS. WB may be administered via either the intravenous or intraosseous route, according to standard practice at Ornge AAS. RBC and plasma may be administered via either the intravenous or intraosseous route, according to standard clinical practice at Ornge AAS. RBC and plasma may be administered via either the intravenous or intraosseous route, according to standard clinical practice at Ornge AAS. Blood and fluid boluses will be administered according to standard practice which will require that they are delivered through a fluid warming device. Administration schedule Each eligible patient requiring prehospital blood transfusion will initially receive either the intervention (up to 2 units of WB) or control (up to 2 units of RBCs and 2 units of plasma), followed by additional blood components as required. The volume of blood product given will follow local protocol. For adult patients this would usually be up to 2 units of WB, or up to 2 units each of RBCs and plasma. RBC and plasma will be administered as per current standard of care. On arrival to the receiving LTH, any remaining prehospital WB or blood components should be transfused prior to transfusing additional blood from the receiving LTH. Concomitant treatment Patients enrolled in SWiFT Canada will only receive component therapy in the trauma bay if additional transfusions are required. WB and RBC are prepared with citrate; therefore, solutions containing calcium must not be administered concurrently through the same cannula. Medicinal products should not be added to WB, RBC or plasma. If an acute transfusion reaction, including allergic reaction, is suspected following intravenous/intraosseous infusion of either WB, RBC or plasma, the transfusion should be stopped immediately. The intravenous/intraosseous cannula should be retained and the transfusion reaction managed as per standard clinical practice. Outcomes The primary outcomes of the study will be: (1) the proportion of patients enrolled in the study who receive a prehospital transfusion and had full study data collected, (2) the number of patients who received transfusion of at least 1 unit of assigned blood products prior to arrival to the receiving LTH, (3) the number of patients who completed transfusion of all assigned blood products at the receiving LTH, (4) the number of patients screened for the study by not being randomised due to lack of group O negative WB availability and (5) the number of WB, RBC and plasma units produced for the study that were wasted. These will be presented as counts and proportions. The secondary outcome will be the proportion of patients who have died (all-cause mortality) or received massive transfusion (10 units or more of blood transfusions) in the first 24 hours after randomisation. A participant is considered randomised and entered into the trial when the trial box is opened. Harms In addition to the trial safety reporting procedures, LTH staff will be responsible for reporting all transfusion-related adverse events/reactions via the Transfusion Transmitted Injuries Surveillance System (TTISS) according to standard procedures (as outlined by Public Health Agency of Canada and Canadian Blood Services). SHSC Transfusion Medicine Laboratory that will follow their own local policies and procedures for the response to a possible adverse transfusion event and will ensure full compliance with their own licence and Health Canada/regulatory reporting standards. The SHSC Transfusion Medicine Laboratory has scheduled deliveries three times weekly for the Ornge AAS Toronto Rotor Wing Base as well as can deliver on an as-needed basis once a trial box has been used. The current system of blood cooler schedule, transport, replacement and monitoring will be otherwise unchanged from the current standard operating procedure, except for delivery of study trial boxes as opposed to the current box of 2 units of RBCs only. Where the receiving hospital transfusion laboratory is different from the issuing hospital transfusion laboratory, then both parties should coordinate to ensure traceability of blood components and reporting. Regulations require that the hospital transfusion laboratory that provided the blood component(s) must be informed immediately of all adverse events and reactions. Advice on clinical management and investigation of serious adverse reactions can be obtained from the hospital transfusion medicine service responsible for blood transfusion at the coordinating hospital. All serious adverse events (SAEs)/reactions which are deemed related to the administration of the prehospital WB and standard of care components (RBC and plasma) must be reported as SAEs. Events that do not require reporting The following are regarded as anticipated SAEs (ie, are recognised complications/consequences of major trauma) and are excluded from recording and reporting: death (related to trauma), organ failure, multi-organ dysfunction syndrome, acute respiratory distress syndrome, infection (any anatomical site), venous thromboembolism: deep vein thrombosis or pulmonary embolism SAEs that are related to a pre-existing condition are not required to be reported. Details of all SAEs (except those which are excluded, see above) will be documented and reported from the date/time of commencement of the protocol defined treatment, up to 14 days post-treatment or until discharge from acute care (whichever occurs first). SAE reporting is only required during the primary hospital admission. Participant timeline Please refer to figure 1. Study flow chart. *For the purposes of participant follow-up, randomisation is when the sealed box of blood components is opened. AAS, air ambulance service; SHSC, Sunnybrook Health Sciences Centre. Sample size For the SWiFT Canada pilot trial, there was no formal sample size calculation. The planned sample size of 60 reflects the annual historical volume of trauma patients treated and transported by Ornge AAS with its Blood on Board programme from its Toronto rotor base. By recruiting for an anticipated 60 patients we expect to enrol for approximately 18 months, allowing us to account for seasonal variations in trauma mechanisms and volumes. Additionally, it should allow sufficient time for the study to be maintained to explore potential seasonal variations in blood donor or blood inventory challenges (such as no group O negative WB donors available). As the blood inventory is national and known to have seasonal fluctuations/shortages, enrolling 60 patients over an anticipated 18 months could inform the planning of a larger national prehospital transfusion clinical trial as the other AAS will share the same national blood inventory limitations. Recruitment The Ornge paramedics taking part in the study will carry a trial intervention box containing blood products (either WB or standard care). Once a trauma patient requiring blood transfusion is identified, paramedics will open the box and administer the blood products. This will ensure that if a patient requires a blood transfusion and is attended by a participating AAS, they are recruited into the trial. Paramedics are blinded to treatment allocation until the trial box is opened. The exterior of the box is identical for both WB and standard care to ensure allocation concealment before enrolment in the study. Randomisation The randomisation scheme A restricted randomisation method will be used in this trial. It will consist of randomly permuted blocks of varying undisclosed sizes to account for seasonal variation in trauma care and type/mechanism of trauma. There will be a 1:1 allocation ratio, to the intervention and control arms. The allocation sequence will be produced from a specification provided within the trial’s REDCap database (housed within AHRC, UHT). Sequence generation Allocation will be conducted by the participating Transfusion Medicine Laboratory team at SHSC using sealed envelopes. Allocation concealment mechanism Allocation will be conducted by the SHSC transfusion laboratory team using sealed envelopes. Only the trial statisticians will have access to the randomisation list and REDCap database that produces the allocation sequences. Implementation The SHSC Transfusion Medicine Laboratory will maintain a constant supply of transport boxes containing the trial interventions to Ornge AAS at the Toronto rotor base. The transfusion laboratory will obtain the randomised allocations using opaque sealed envelopes. The SHSC Transfusion Medicine Laboratory will be supplied with pre-printed ‘SWiFT Canada randomisation number’ labels to which they will add by hand the randomisation number. A registered user at the transfusion laboratory will assign a unique randomisation for each box to be used by the Ornge AAS. The allocated trial intervention will be packed into transport boxes, ensuring that the randomisation number is clearly documented on the outside of the box. The date and time of expiry will also be written on each transport box. The packed, sealed transport boxes will be dispatched to the Ornge AAS Toronto rotor base using an established courier service as required for the site. Unused boxes will be returned to the SHSC Transfusion Medicine Laboratory and if unopened, replaced ‘like-for-like’. A new randomisation should only be performed once the box has been used (ie, contents have been transfused to a participant) or if the box was returned opened but the contents were not used. The trial boxes are routinely swapped out from the Toronto rotor base three times a week to ensure temperature control is maintained in the blood coolers. Blinding Who will be blinded and how blinding will be achieved Ornge AAS paramedics are blinded to the randomised allocation until the trial box is opened, after which point it is not feasible to maintain blinding. To ensure that the team remains blinded until the box is opened, the boxes containing intervention or control will be the same size and shape and will be closed with a tamper-proof zip tie. It is not possible to blind the team at the receiving hospital to the intervention. Participants will be blinded to allocation until the trial box is opened, but they may discover this information post-randomisation (eg, by reading their medical notes or requesting this information from the Research Team), although there is no obligation to inform the participant which treatment they received. Trial statisticians will also be blinded to which arm patients were assigned to. Circumstances in which unblinding is permissible Not applicable. Unblinding will effectively occur when the trial box is opened. Data collection methods Plans for assessment and collection of trial data On arrival at the LTH, the Ornge AAS paramedics will hand over clinical responsibility of the patient to the receiving hospital team and complete the Prehospital Form (on the electronic case report form (eCRF)). If the trial intervention has not been completed by the time the patient arrives at the hospital, it should be completed after arrival at hospital if it is still clinically indicated. Further management is dictated by normal clinical protocols at the discretion of the in-hospital team managing the patient. Each unit of blood administered prehospital must be recorded on the Prehospital Form, along with the donation number of the unit and the transfusion start time. Ornge AAS paramedics complete the eCRF after transfer of care with vital signs automatically uploaded from the paramedic transport monitor. Additional pre-hospital data such as point of care laboratory results, patient demographics and additional treatments performed by Ornge paramedics is then obtained and sent to the UHT Data Coordinating Centre for linkage with the in-hospital data collection. The Site Investigator and Research Team at the receiving LTH will be responsible for the follow-up in-hospital data collection for trial participants. The first available prothrombin time, lactate, pH, base excess (ie, from first blood samples taken after admission as part of routine standard care) will be recorded. No additional blood sampling is required. The transfusion laboratory at the receiving hospital will be responsible for recording the final disposition of all blood components that were administered to the participant, to ensure full traceability. This will be the responsibility of the transfusion medicine/laboratory clinical team, with no changes to the current standard blood component tracking practices. The follow-up data collected at day 1 (24 hours post randomisation) will include participant’s demographics and baseline data, participant status (alive/dead) at 6 hours and 24 hours, if the participant has died, the Exit Form must be completed to provide further detail, total number of blood components transfused (ie, WB, RBC, plasma, platelets), cell salvage/autologous blood transfusion, haemostatic agents received (including recombinant Factor VIIa, fibrinogen concentrate, prothrombin complex concentrate, tranexamic acid) and screen results for haemolysis The follow-up data collected at day 30 will include participant status (alive/dead). If a participant has died, the Exit Form must be completed to provide further detail, total number of blood components transfused (ie, RBC, plasma, platelets), critical care admission (yes/no), plus date/time of admission where applicable, hospital resource use (up to discharge from LTH or death (whichever is first)), thromboembolic events (clinically diagnosed), any transfusion reactions which have been reported to TTISS (occurring in first 14 days post-randomisation) and any acute haemolytic reaction (yes/no) The follow-up data collected at day 90 will include participant status, if still in LTH (alive/dead). If a participant has died, the Exit Form must be completed to provide further detail. If a participant is transferred to another participating trial site, the responsibility for ongoing data collection should reside with the Site Investigator/Research Team at the new hospital. If a participant is transferred to a non-participating site, the Research Team will rely on any information sent back to the lead LTH regarding alive/dead status, if that information is shared. In accordance with standard operating procedures and regular reporting to CBS, the SHSC transfusion medicine lab will track units of WB, RBC and plasma that were delivered to the Ornge Toronto rotor base. The study will be able to report on whether a study WB unit was transfused to a study patient, transfused to a non-study patient, or wasted. The disposition of RBC and plasma will be reported through standard reporting processes. Plans to promote participant retention and complete follow-up With the exception of cases where the participant has a non-traumatic haemorrhage, there are no other specific circumstances where a participant should be withdrawn from the trial. If a participant is withdrawn, a withdrawal form should be completed which will detail the reason for withdrawal, and whether the data collected before withdrawal can be used. Statistical methods Statistical methods used to compare groups for primary and secondary outcomes The following factors will be used to assess baseline comparability of the randomised groups: age in years reported as a median (IQR), sex (male or female), type of injury (blunt or penetrating), nature of traumatic injury (high or low energy transfer), Injury Severity Score, reported as a median (IQR), initial prehospital and hospital arrival systolic blood pressure (mm Hg) reported as a median (IQR), initial prehospital and hospital arrival heart rate (per minute) reported as a median (IQR), initial prehospital and hospital arrival Glasgow Coma Scale reported as a median (IQR) and total out of hospital time (time from call received to time to handover to receiving trauma team reported in minutes as a median (IQR)). A CONSORT diagram will be produced to show the flow of participants through the trial. Primary outcomes/feasibility analysis The primary outcome of feasibility metrics will be presented as frequencies and proportions. The study will be considered feasible if the following are met: (1) >90% patients enrolled were able to link prehospital to in-hospital records and >90% complete data obtained, (2) at least 1 unit of blood (WB, RBC or plasma) transfused prior to arrival at LTH >90% of the time, (3) >90% of patients completed transfusion of all assigned blood products at the receiving LTH if indicated and not already done prior to arrival of hospital and (4) <10% wastage of WB units produced for the study. Secondary outcome analyses The following will be included in the blood component count: RBC, platelets, WB and plasma. In this trial, for the purposes of analysis, two units of WB will be counted as equivalent to four total units due to the volume difference between the intervention and control arm and the fact that two units of WB contain the equivalent of two units of plasma plus two units of RBCs. All-cause mortality at 6 hours, 24 hours, 30 days and 90 days, the proportion of participants who receive 10 or more units of any blood components and presence of coagulopathy will each be analysed separately. Organ failure-free days, days in critical care and an acute care hospital will be reported as a median and IQR, by treatment arm and overall. Units of each blood component received in the 24 hours after randomisation will be summarised with a median and IQR and analysed using a negative binomial model. Amount cell salvage (in mLs) at 24 hours after randomisation as well as lactate, base excess and pH level in the first sample taken on arrival at the LTH will be analysed separately using linear regression models. For each of the additional haemostatic agents, the number of participants who received each agent will be presented by trial arm and overall. Thrombosis (arterial or venous thrombosis) up to 30 days after randomisation and transfusion reactions/events relating to prehospital blood components which have been reported to TTISS occurring in the first 14 days after randomisation will be summarised. Count and frequencies will be reported on: the total number of WB units supplied by CBS to support the SWiFT Canada study, the total number of WB units transfused for SWiFT Canada, the total number of WB units recirculated into distribution and then transfused to non-SWiFT Canada patients and lastly, the total number of WB units wasted. These data will only involve tracking of individual blood units via the blood inventory management system and no patient specific information will be obtained or required for non-SWIFT Canada patients. Definition of who will be included in each analysis All analyses will be performed on a modified intention to treat basis, with exclusion of participants who experienced a traumatic cardiac arrest. Data will be presented and analysed according to the arm to which the participant was randomised, regardless of whether they received the randomised intervention or not. How missing data will be handled in the analysis For the analyses, any missing data for the outcome measures will be treated as missing data and not be imputed. We anticipate very little missing data for the feasibility measures. If an outcome has data missing for more than 25% of participants, then the analysis will not be undertaken, otherwise complete case analysis will be performed. All missing outcome data will be summarised. Methods for any additional analyses Our secondary outcome analyses will be replicated for three subgroups: Presence of a traumatic brain injury defined as Abbreviated Injury Scale head score 3 or above. Presence of a traumatic brain injury defined as Abbreviated Injury Scale head score 3 or above. Blunt versus penetrating traumatic injury. Blunt versus penetrating traumatic injury. Injury Severity Score: ≤15 versus 16–25 versus ≥26. Injury Severity Score: ≤15 versus 16–25 versus ≥26. Data coordination and trial steering committee Composition of the coordinating centre and trial steering committee The trial will be managed by the FIRST60 research programme, with day-to-day input from a trial manager, research coordinator and the principal investigator. A trial management group (TMG), made up of the principal investigator, co-applicants, trial statisticians and trial manager, will meet every 2 weeks during the trial set-up phase, and monthly thereafter, to monitor trial conduct, safety, recruitment and follow-up. Additionally, a smaller trial steering committee (TSC) has been convened with select trial members representing expertise in prehospital, transfusion medicine, trauma and CBS. The role of the TSC is to safeguard the well-being of patients and monitor overall conduct of this trial, for example, organisation and implementation of the trial protocol. The TSC will be responsible for making executive decisions about the trial. Interim analyses and stopping guidelines This is not applicable; there will not be an interim analysis or stopping guideline as the study is anticipated to be completed within 18 months and only enrol 60 patients. Trial monitoring Site initiation visits will be virtual (delivered via Zoom) for the core research team. The Site Investigator will be responsible for ensuring this training is cascaded to the rest of the research team and signed off on the training log. The UHT Data Coordinating Centre will ensure sufficient members of the team have signed the training log and record all members who attend the training sessions. Any new members of the research team will be contacted to arrange a training session. Any members of the UHT Data Coordinating Centre team who are using the study database will be required to undergo REDCap training before being given access. Key site data will be monitored centrally on a bimonthly basis; more detailed monitoring will be conducted dependent on site performance. The first monitoring visit will be conducted after the first patient reaches 1 month post recruitment. Following that, sites will be contacted once per year to discuss progress and any issues via phone or video conferencing on regular study meetings. Checklists will be sent out to monitor the site file, check primary outcome and key secondary outcomes and to reconfirm eligibility and any SAEs. On a quarterly basis, randomisation log and screening log will be monitored remotely, with SHSC and Ornge AAS respectively. On-site monitoring visits will be conducted if there is serious concern or a serious breach of good clinical practice or the protocol. Additional monitoring visits may be triggered during the course of a study whereby serious breaches, serious protocol deviations, data quality or inconsistent/missing data issues or other safety concerns are identified by the trial manager, TMG or TSC. Close out will be conducted in line with UHT Data Coordinating Centre. Sites will complete a close-out form and checklist. Calls/visits will be conducted if required. Ethics and dissemination Research ethics approval The protocol and supporting documents for the SWiFT Canada trial were reviewed by the St Michael’s Hospital Research Ethics Board, on behalf of Clinical Trials Ontario (Clinical Trials Ontario REB ID: CTO-4921), and a favourable ethics opinion was provided on 9 September 2024 and approval granted by the Ontario Ministry of Health on 29 October 2024. Protocol amendments Any amendments to the approved protocol will be communicated to all relevant parties in an expedited manner by the trial manager via email. Who will obtain informed consent or assent from potential trial participants or authorised proxies, and how? Major traumatic haemorrhage is a life-threatening condition that requires urgent treatment. The vast majority of participants will lack capacity. Due to the emergency nature of major trauma, time will not allow for written informed consent to be obtained first from a legal representative for incapacitated adults before randomisation into the trial. As products in both arms of the study were approved for use by Health Canada, trial interventions were consistent with clinical practice standards internationally, and trial procedures did not expose patients to excess risks. It is expected that participants will lack capacity throughout the recruitment and intervention periods of the trial, and although an occasional participant may retain capacity, their clinical condition will require immediate treatment. It would be inappropriate to attempt to gain informed consent at this time, as it could delay life-saving treatment. It would also be clinically unjustifiable to delay treatment until full informed consent can be obtained from a personal legal representative. Even if such a representative or person with parental responsibility were immediately available, the emotional distress of the situation is such that they would be unlikely to make an informed decision in the minimal time available. Furthermore, sudden traumatic injury cannot be predicted or foreseen, and there is no opportunity to seek consent in advance. Consequently, SWiFT Canada cannot be conducted on the basis of prospective informed consent. Participants will be enrolled under an emergency waiver of consent. This trial will be performed under waiver of consent based on Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans – TCPS 2 in accordance with section Article 3.8. Multimodal notification of the trial, enrolment and data collection will include: (1) a general notification letter (included with the SWiFT Canada transfusion cooler) that will be given to randomised patients or their family member, (2) a SWiFT Canada bracelet to be applied to the patient once enrolled with a link to the study url (https://first60.ca/current-studies/swift/) and (3) a letter of notification mailed to the person/family within 30 days of enrolment. Patients will be informed about the study and notified how to opt out of future data collection if they wish. All study data obtained up until a patient or representative opts out will be retained and included in the study. Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies SWiFT Canada participants will be eligible for enrolment in an ancillary mechanistic study at sites that are recruiting patients to that study. The details of the collection and analysis of the samples taken will be according to the study protocol with an additional and separate consent process. Data management The Site Investigator has overall responsibility for data collection at Ornge and/or receiving LTH site. Participant data will be sent to the UHT Data Coordinating Centre. There, it will be entered in the SWiFT Canada REDCap database. All case report forms will be electronic. Training and instructions for completion of eCRFs will be given to each site during site activation. The UHT Data Coordinating Centre staff will be in regular contact with local site personnel to check on progress and to help with any queries that may arise. Incoming electronic forms will be checked for completeness, consistency, timelines and compliance with the protocol. Direct access to eCRF data will be granted to authorised representatives from the sponsor, UHT Data Coordinating Centre, host institution and the regulatory authorities to permit trial-related monitoring, audits and inspections in line with participant consent. Confidentiality All investigators and trial site staff must comply with the requirements of the Ontario Personal Health Information Protection Act 2004 with regard to the collection, storage, processing and disclosure of personal information and will uphold the regulations’ core principles. The confidentiality standards will be maintained by coding each patient enrolled in the trial through assignment of a unique participant identification number. Only pseudo-anonymous data will be entered into the trial database. Limited patient identifiable data points will be required, to enable linkage to the LTH trauma registry datasets. Identifiable information will be held separately from the trial database and will not be retained for the analysis. Availability of data and materials The final dataset will reside with the data collection centre. The TSC will have access and can approve exceptional access for other members of the trial team to facilitate analyses or to cover for absences. Access to the final dataset for additional analyses will be permitted under the agreement of the TSC and according to the trial publication policy. Ancillary and post-trial care Canada has a publicly funded healthcare system, and participants in the SWiFT Canada trial will continue to receive all medically necessary care, including treatment for any injuries or complications, through their usual healthcare coverage. Any provisions for ancillary or post-trial care will be reviewed and arranged by the TSC on a case-by-case basis as appropriate. In the event that a participant experiences harm as a result of participation in this trial, compensation will be addressed in accordance with applicable local and institutional policies and relevant Canadian law. UHT, as the trial sponsor, will ensure that procedures are in place to support the management and reporting of any adverse events and that participating sites comply with all regulatory and institutional requirements. Dissemination Plans The study team plans to communicate the trial results to participants, healthcare professionals, the public and other relevant groups through conference presentations, peer-reviewed publications and plain language summary on the FIRST60 website www.FIRST60.ca. Discussion SWiFT Canada is a pragmatic RCT that will determine whether a prehospital transfusion clinical trial is feasible in the Canadian prehospital setting. Additionally, it will provide evidence on the eligibility, enrolment rates and wastage of blood within the Canadian prehospital environment. Over the last decade, there has been increasing interest in the use of WB as a primary resuscitative product for haemorrhagic shock—both the in-hospital and out-of-hospital environments. While CBS has received Health Canada approval to manufacture WB, the National Advisory Council on Blood and Blood Products recommendations on WB state that prioritisation for WB should be for clinical studies to provide the evidence for which patients are most likely to benefit from WB use. The costs of WB production are likely to be higher than RBC, as special leucocyte depletion filters are required to preserve the platelets within the WB. Moreover, donors required to support WB transfusion for prehospital patients would need to be of a specific type (ie, male, group O and have low titre for anti-A and B antibodies in plasma), since the recipient blood group is not known in advance of giving the transfusion. These donors are a precious resource and are required to support other groups of patients; therefore, it is important that this resource is utilised optimally. The SWiFT Canada trial is uniquely positioned to generate critical evidence on the feasibility of a trial to compare effectiveness of WB in a prolonged prehospital setting—an area where data are currently sparse, especially in the Canadian context. By leveraging the existing infrastructure of critical care transport organisations and integrating pragmatic trial design, this study will provide real-world insights into the feasibility of a broader prehospital transfusion trial in Canada. Supplementary material